The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 6, 2014, Pages 911-918

  Goode, Kevin M ^a   Nicholls, Rachel ^b   Pellicori, Pierpaolo ^b   Clark, Andrew L ^b   Cleland, John G F ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

C terminal pro arginine vasopressin; C terminal pro endothelin 1; In vitro stability; Mid regional pro adreno medullin; Mid regional pro atrial natriuretic peptide; Ultrasensitive procalcitonin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; COPEPTIN; EDETIC ACID; ENDOTHELIN 1; PROADRENOMEDULLIN; PROCALCITONIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL EVALUATION; DEGRADATION; ENVIRONMENTAL TEMPERATURE; FEMALE; HEART FAILURE; HUMAN; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; ROOM TEMPERATURE; SEPSIS; SUPERNATANT; VEIN PUNCTURE; BLOOD; BLOOD ANALYSIS; MIDDLE AGED; PROCEDURES; TEMPERATURE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; SEPSIS; TEMPERATURE;

EID: 84903590847     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0767     Document Type: Article

References (28)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-1847.
2. Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013;62:e147-e239.
3. Chronic heart failure: national clinical guideline for diagnosis and management in primary and secondary care (NICE clinical guideline 108 - partial update). London: National Institute for Health & Care Excellence, 2010 [updated 2 August, 2013]. Available from: http://guidance.nice.org.uk/cg108.
4. van der Merwe DE, Henley R, Lane G, Field R, Frenneaux M, Dunstan F, et al. Effect of different sample types and stability after blood collection of N-terminal pro-B-type natriuretic peptide as measured with Roche elecsys system. Clin Chem 2004;50:779-780. (Pubitemid 38429352)
5. Barnes S, Collinson PO, Galasko G, Lahiri A, Senior R. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys (TM) 1010 and 2010 analysers. Ann Clin Biochem 2004;41:459-463. (Pubitemid 39574001)
6. Sokoll LJ, Baum H, Collinson PO, Gurr E, Haass M, Luthe H, et al. Multicenter analytical performance evaluation of the Elecsys proBNP assay. Clin Chem Lab Med 2004;42:965-972.
7. Azzazy HM, Christenson RH, Duh SH. Stability of B-type natriuretic peptide (BNP) in whole blood and plasma stored under different conditions when measured with the Biosite Triage or Beckman-Coulter Access systems. Clin Chim Acta 2007;384:176-8. (Pubitemid 47247414)
8. Murdoch DR, Byrne J, Morton JJ, McDonagh TA, Robb SD, Clements S, et al. Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice. Heart 1997;78:594-7. (Pubitemid 28034211)
9. Gruson D, Rousseau MF, de Coninck V, Ahn SA, Ketelslegers JM. Influence of sampling and storage conditions on B-type natriuretic peptide immunoreactivity for 3 automated assays. Clin Chem 2006;52:766-7.
10. Santos H, Cauliez B, Tron C, Brunel V, Lavoinne A. Is heparin plasma suitable for the determination of B-type natriuretic peptide on the Beckman-Coulter Access 2? Clin Chem Lab Med 2010;48:399-401.
11. Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Stability of brain natriuretic peptide (BNP) in human blood samples. Clin Chim Acta 1999;285:169-172. (Pubitemid 29347181)
12. Buckley MG, Marcus NJ, Yacoub MH. Cardiac peptide stability, aprotinin and room temperature: importance for assessing cardiac function in clinical practice. Clin Sci (Lond) 1999;97:689-695. (Pubitemid 30018880)
13. Buckley MG, Marcus NJ, Yacoub MH, Singer DR. Prolonged stability of brain natriuretic peptide: importance for non-invasive assessment of cardiac function in clinical practice. Clin Sci (Lond) 1998;95:235-239. (Pubitemid 28444830)
14. Gaggin HK, Januzzi JL, Jr. Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 2013;1832:2442-2450.
15. Ahmad T, Fiuzat M, Felker GM, O'Connor C. Novel biomarkers in chronic heart failure. Nat Rev Cardiol 2012;9:347-359.
16. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004;50:234-236. (Pubitemid 38125732)
17. Potocki M, Breidthardt T, Reichlin T, Hartwiger S, Morgenthaler NG, Bergmann A, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure. J Intern Med 2010;267:119-129.
18. von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1973-1980. (Pubitemid 350046336)
19. Khan SQ, Dhillon O, Kelly D, Squire IB, Struck J, Quinn P, et al. Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 2008;51:1857-1864. (Pubitemid 351615250)
20. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005;9:R37-R45.
21. Seronde MF, Gayat E, Logeart D, Lassus J, Laribi S, Boukef R, et al. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol 2013;168:3404-3411.
22. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006;52:1528-1538. (Pubitemid 44148316)
23. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 2005;51:1823-1829. (Pubitemid 41368172)
24. Mockel M, Searle J, Hartmann O, Anker SD, Peacock WF, Wu AH, et al. Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. Emerg Med J 2013;30:633-637.
25. Xue Y, Taub P, Iqbal N, Fard A, Clopton P, Maisel A. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure. Eur J Heart Fail 2013;15:1343-1349.
26. Papassotiriou J, Morgenthaler NG, Struck J, Alonso C, Bergmann A. Immunoluminometric assay for measurement of the C-terminal endothelin-1 precursor fragment in human plasma. Clin Chem 2006;52:1144-51. (Pubitemid 43794428)
27. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52: 112-119. (Pubitemid 43032474)
28. Evans MJ, Livesey JH, Ellis MJ, Yandle TG. Effect of anticoagulants and storage temperatures on stability of plasma and serum hormones. Clin Biochem 2001;34:107-112. (Pubitemid 32322701)